|Novavax, Inc. Reports Good Top-Line Data from Phase 1 Ebola Vaccine Trial|
|By David Fowler|
|Tuesday, 21 July 2015 15:16|
Clinical stage vaccine firm Novavax, Inc. (NASDAQ:NVAX) which is focused on discovery as well as commercialization of recombinant nanoparticle vaccines has confirmed good top-line data from Phase 1 clinical trial of Ebola virus glycoprotein (GP) recombinant nanoparticle vaccine candidate adjuvanted with Matrix-M as part of World Health Organization’s Fifth Teleconference on Ebola Vaccine Clinical Trials.The trial showed that Ebola GP Vaccine was immunogenic and along with Novavax’ proprietary Matrix-M adjuvant led to antigen dose-sparing.
Ebola GP Vaccine clinical trial is observer-blinded trial for assessing safety as well as immunogenicity of vaccine in patients between 18 and 49 years of age. Participants got either of the intramuscular injections in a range of 6.5µg to 50µg of antigen.
Ebola GP Vaccine was immunogenic at all levels. The adjuvanted single dose vaccine regimen induced GMEU between 1700 and 3400.
Gregory Glenn, M.D., Senior Vice President, Research and Development, opined that they are glad to have the chance for sharing good data with WHO.
He added that Novavax’ recombinant nanoparticle technology as well as proprietary Matrix-M adjuvant differentiates the vaccine.
Glenn further stated that Phase 1 clinical data demonstrates that the vaccine was well-tolerated and showed high Ebola antibody responses.
Stanley C. Erck, President and CEO, opined that the positive data showed third time Novavax has improved influence of platform technology for quickly addressing a emerging threat.
Erck opined that the data along with clinical data from H7N9 VLP vaccine candidate and preclinical data from vaccine show additional validation of the nanoparticle vaccine platform.
He added that the vaccine was highly immunogenic at low doses.